WHO warns against usage of 2 cough syrups made by Marion Biotech over deaths of 19 children in Uzbekistan

Published On 2023-01-12 04:30 GMT   |   Update On 2023-01-12 10:43 GMT

New Delhi: The World Health Organization on Wednesday said that two cough syrups made by India's Marion Biotech should not be used for children, after the products were linked to 19 deaths in Uzbekistan.Analysis by Uzbekistan's health ministry showed the syrups, Ambronol and DOK-1 Max, contained a toxic substance, ethylene glycol. The syrups were administered in doses higher than the standard...

Login or Register to read the full article

New Delhi: The World Health Organization on Wednesday said that two cough syrups made by India's Marion Biotech should not be used for children, after the products were linked to 19 deaths in Uzbekistan.

Analysis by Uzbekistan's health ministry showed the syrups, Ambronol and DOK-1 Max, contained a toxic substance, ethylene glycol. The syrups were administered in doses higher than the standard for children, either by their parents, who mistook it for an anti-cold remedy, or on the advice of pharmacists, according to the analysis.
So far, Marion has not provided guarantees to WHO on the safety and quality of these products, the agency said. Shortly after the series of deaths were reported in Uzbekistan, India's health ministry suspended production at the company. According to a recent report, India's Uttar Pradesh state has suspended Marion's production license.
Marion did not immediately respond to a Reuters request for comment. Last week, the Uzbek state security service arrested four people in an investigation into the cough-syrup related deaths of 19 children.
The Uzbekistan case follows deaths of at least 70 children in Gambia that a parliamentary committee had linked to cough and cold syrups manufactured by New Delhi-based Maiden Pharmaceuticals. The company denied any wrongdoing and Indian government inspectors found no contamination in test samples.
Tags:    
Article Source : Reuters

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News